Stock listing

NASDAQ:SCTX Scribe Therapeutics Inc. Stock

Follow Scribe Therapeutics Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:SCTX

$12.07 USD -1.98 (-14.1%)

Close on Nov 20, 2026

Past 3 months -19.5% · daily closes, Jul 23, 2026 – Nov 20, 2026, adjusted for splits
Day range
$12.00 – $13.40 USDNov 20, 2026
Volume
301,402 sharesNov 20, 2026
Market cap
$228.5M USDAt the close on Nov 20, 2026 · price × 18.93M shares outstanding
Traded on an average day
$8.82M USDMedian day 318,800 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:SCTX · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$12.07-1.98-14.1%$12.87$13.40$12.00301,402
$14.05-1.72-10.9%$15.78$16.34$14.00271,910
$15.77+0.40+2.6%$15.27$15.99$14.71272,885
$15.37-0.99-6.1%$16.53$17.25$15.30435,090
$16.36-0.63-3.7%$16.23$16.66$15.34330,570
$16.99+0.13+0.8%$16.37$17.45$15.55282,118
$16.86-0.50-2.9%$17.50$17.76$16.70367,605
$17.36+0.68+4.1%$16.42$18.30$16.01343,281
$16.68+0.98+6.2%$15.99$17.40$15.69305,834
$15.70+0.22+1.4%$15.60$16.44$15.29321,589
$15.48-1.30-7.7%$17.50$17.50$15.39291,689
$16.78+0.58+3.6%$16.58$17.48$16.25263,055
$16.20+0.66+4.2%$15.71$16.47$15.57233,067
$15.54+0.12+0.8%$15.58$15.87$14.31332,056
$15.42-2.02-11.6%$17.00$17.00$14.77479,200
$17.44-0.10-0.6%$17.45$18.27$16.98252,800
$17.54+1.58+9.9%$16.21$17.73$15.78318,800
$15.96+0.36+2.3%$15.81$16.32$15.15578,600
$15.60+0.19+1.2%$15.40$16.89$14.88348,500
$15.41-2.55-14.2%$17.88$18.55$15.12861,500
$17.96-1.34-6.9%$19.11$19.11$16.40641,300
$19.30-0.51-2.6%$20.43$21.00$19.00485,300
$19.81+0.42+2.2%$19.64$21.37$19.33203,700
$19.39-0.69-3.4%$20.09$20.92$18.27259,400
$20.08-0.64-3.1%$20.86$21.00$19.67201,500
$20.72-0.05-0.2%$20.79$21.95$19.73180,900
$20.77+1.65+8.6%$18.81$21.99$18.81391,300
$19.12-1.55-7.5%$20.28$20.28$18.00298,500
$20.67-0.50-2.4%$21.20$22.07$19.52512,500
$21.17+1.94+10.1%$19.21$21.33$19.18396,500
$19.23+1.66+9.4%$17.54$19.75$16.90351,900
$17.57+1.24+7.6%$15.94$18.16$15.75420,500
$16.33+0.12+0.7%$16.12$17.17$15.37464,400
$16.21-0.58-3.5%$17.17$17.17$13.501,106,500
$16.79-0.39-2.3%$17.50$17.81$16.49474,900
$17.18-1.23-6.7%$18.41$19.36$17.00669,200
$18.41-4.62-20.1%$23.03$23.40$17.701,180,700
$23.03+1.26+5.8%$21.53$23.75$21.29671,200
$21.77+0.49+2.3%$21.28$22.00$20.50306,900
$21.28-0.33-1.5%$23.17$23.28$20.21458,500
$21.61-4.92-18.5%$26.27$26.27$21.36525,500
$26.53-1.54-5.5%$28.51$29.09$26.08532,700
$28.07+0.02+0.1%$28.52$30.36$25.00584,500
$28.05-4.95-15.0%$32.88$34.49$27.32528,600
$33.00+0.86+2.7%$31.76$35.40$31.762,236,400
$32.14+3.04+10.4%$29.44$33.36$29.30303,900
$29.10-2.56-8.1%$31.80$32.90$27.94326,000
$31.66+2.24+7.6%$30.19$32.02$28.85161,500
$29.42-0.32-1.1%$29.97$30.53$28.55137,000
$29.74+0.27+0.9%$29.76$31.00$29.02141,200
$29.47+0.06+0.2%$29.31$30.55$28.83189,500
$29.41-1.93-6.2%$30.59$32.16$29.14153,200
$31.34+2.67+9.3%$28.00$31.68$27.61218,000
$28.67-2.14-6.9%$30.21$31.45$28.50147,900
$30.81-0.09-0.3%$31.00$32.25$29.75148,000
$30.90+1.90+6.6%$29.75$32.41$29.67278,700
$29.00-1.54-5.0%$30.65$31.25$28.46165,000
$30.54+2.10+7.4%$28.39$31.61$27.20151,100
$28.44-0.40-1.4%$28.78$34.64$27.99201,700
$28.84-2.86-9.0%$31.29$31.66$27.54194,700
$31.70+0.495+1.6%$32.81$33.71$28.83246,200
$31.21-6.045-16.2%$38.00$38.60$30.75316,029
$37.25+3.12+9.1%$35.76$38.90$34.55545,547
$34.13+1.30+4.0%$33.90$36.89$33.90179,400
$32.83+1.78+5.7%$31.30$39.60$30.88419,200
Ticker
NASDAQ:SCTX
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All Scribe Therapeutics Inc. news

Scribe Therapeutics Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
4 in the last 12 months · 4 in all · newest Nov 18, 2026 · oldest 2026
Decks
1 deck · latest 2026

Valuation

EV/sales 1.2× against a median of 11.9×: 4th lowest of 9 Biotechnology companies shown. Statements: Year to Dec 31, 2025 · balance Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$59.42M USD
P/E
Loss
EV/sales
1.2×
EV/EBITDA
Negative EBITDA
Price/book
1.8×
Gross margin
−18.8%
Operating margin
−50.9%
Net margin
−42.6%
Debt to equity
0.0×
Beta vs S&P 500
Under 6 months of closes

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Scribe Therapeutics Inc. · NASDAQ:SCTXUS$228.5MUS$59.42Mn/a1.2×n/a1.8×−42.6%0.0×n/a
Clinuvel Pharmaceuticals Limited · ASX:CUVUS$238.9MUS$73.38M10.3×1.1×2.6×1.3×36.0%0.0×n/a
CAMP4 Therapeutics Corporation · NASDAQ:CAMPUS$237.8MUS$119.8Mn/a22.5×n/a2.2×n/a0.1×1.70
Valerio Therapeutics · EURONEXT:ALVIOUS$228.9MUS$242.3Mn/a85.8×50.8×n/a−190.4%n/an/a
Aprilbio Co., Ltd. · KRX:397030US$222.4MUS$162.1Mn/an/an/a3.1×n/a0.0×n/a
Enanta Pharmaceuticals, Inc. · NASDAQ:ENTAUS$222.2MUS$82.43Mn/a1.3×n/a2.8×−108.3%0.7×1.11
Clover Biopharmaceuticals Ltd. · HKEX:2197US$222.0MUS$206.6Mn/a404×n/an/an/an/an/a
Northwest Biotherapeutics, Inc. · OTC:NWBOUS$220.0MUS$283.8Mn/a99.4×n/an/an/an/a0.90
Keros Therapeutics, Inc. · NASDAQ:KROSUS$219.7M−US$24.67Mn/a−0.6×n/a0.8×−152.7%0.1×1.16
Immuneering Corporation · NASDAQ:IMRXUS$218.7MUS$160.5Mn/an/an/a1.3×n/a0.0×1.17
Allogene Therapeutics, Inc. · NASDAQ:ALLOUS$217.5M−US$7.44Mn/a−1.6×n/a0.6×n/a0.2×1.93
Median of the othersUS$222.1MUS$140.1M10.3×11.9×26.7×1.3×−130.5%0.1×1.17

Forecasts

4 strong buy · Analysts' consensus from EODHD, read Nov 14, 2026. Not 6ix's view and not investment advice.

Price target
57.00 USD · Analysts' mean
EPS, year to Dec 2026
-6.63 · 1 analyst
Revenue, year to Dec 2026
7.94M · 4 analysts

Team and board

OfficerRole
Benjamin L. OakesCo-founder, President and CEO
David ParrotChief Financial Officer
Svetlana LucasChief Operating Officer
Brett StaahlCo-founder, VP of External Innovation
Chitra SharmaSVP of Development
George ManningVP, Controller
Sunny MokSVP of Operations
David F. SavageCo-Founder, Scientific Advisor
James WatsonHead of Business and Corporate Development, Life Sciences Portfolio, Andreessen Horowitz
Jennifer A. DoudnaCo-founder, Scientific Advisor
Richard HectorHead of IP

Events

QuarterResultsShare move
Q3 2026Nov 12, 2026 · After close−3.7%
Q2 2026Sep 2, 2026 · After close−0.3%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (2026)Investor deck31 slides2026

Open Decks

IPO

Priced at US$15.00 a share on Jul 23, 2026.

Price
US$15.00 a share
Shares offered
8,580,000 shares of common stock
Offering size
US$128.7 million
Underwriters' option
Up to 1,287,000 more shares
Listing
SCTX on the Nasdaq Global Market
Underwriters
Leerink Partners, Goldman Sachs & Co. LLC, Guggenheim Securities, Wells Fargo Securities · In the order on the cover
Shares delivered
On or about Jul 27, 2026

Steps

StepWhen
Draft sent to the SEC in confidenceJan 9, 2026
Filed publiclyJul 2, 2026
Amended twiceNewest Jul 20, 2026
Shares registered with an exchangeJul 21, 2026
Declared effective by the SECJul 23, 2026
Final prospectus, with the priceJul 27, 2026

Open IPO · From the cover of the final prospectus (424B4) filed Jul 27, 2026

Financials

Annual, in USD

Income statement

LineFY2025FY2024
Revenue51.2M27.4M
Cost of revenue60.8M
Gross profit-9.62M
Research and development60.8M57.1M
Selling, general and administrative16.4M13.2M
Operating income-26.1M-42.8M
Depreciation and amortization3.08M2.89M
EBITDA-23.0M-39.9M
Interest expense2.39M2.38M
Income before tax-23.6M-37.6M
Income tax-1.80M
Net income-21.8M-47.8M
Earnings per share, basic-1.24-2.72

Balance sheet

LineFY2025FY2024
Cash and equivalents12.8M12.6M
Short-term investments45.2M92.6M
Receivables7.35M
Current assets66.9M110.4M
Total assets78.2M128.0M
Accounts payable4.57M3.79M
Current liabilities69.1M35.0M
Long-term debt34.5M
Total debt41.4M
Total liabilities101.3M253.8M
Shareholders' equity-23.1M-125.9M
Shares outstanding17.6M17.6M

Cash flow

LineFY2025FY2024
Cash from operations-45.2M-45.2M
Capital spending-1.27M-1.35M
Free cash flow-46.5M-46.6M
Cash from investing45.3M
Cash from financing142.0K-222.0K
Change in cash194.0K-32.4M

Open Financials

Filings

FilingDateTypeFiled with
SCHEDULE 13G · Big-stake noticeNov 16, 2026Big-stake noticeSEC
10-Q · Quarterly reportNov 12, 2026Quarterly reportSEC
8-K · Current reportNov 12, 2026ResultsSEC
10-Q · Quarterly reportSep 2, 2026Quarterly reportSEC
8-K · Current reportSep 2, 2026ResultsSEC
SCHEDULE 13G · Big-stake noticeAug 3, 2026Big-stake noticeSEC
SCHEDULE 13D · Big-stake noticeJul 30, 2026Big-stake noticeSEC
SCHEDULE 13D · Big-stake noticeJul 30, 2026Big-stake noticeSEC
4 · Change in ownershipJul 29, 2026Insider tradeSEC
4 · Change in ownershipJul 29, 2026Insider tradeSEC
All 49 filings
FilingDateTypeFiled with
4 · Change in ownershipJul 29, 2026Insider tradeSEC
SCHEDULE 13D · Big-stake noticeJul 29, 2026Big-stake noticeSEC
4 · Change in ownershipJul 29, 2026Insider tradeSEC
4 · Change in ownershipJul 28, 2026Insider tradeSEC
4 · Change in ownershipJul 28, 2026Insider tradeSEC
4 · Change in ownershipJul 27, 2026Insider tradeSEC
4 · Change in ownershipJul 27, 2026Insider tradeSEC
4 · Change in ownershipJul 27, 2026Insider tradeSEC
4 · Change in ownershipJul 27, 2026Insider tradeSEC
4 · Change in ownershipJul 27, 2026Insider tradeSEC
4 · Change in ownershipJul 27, 2026Insider tradeSEC
4 · Change in ownershipJul 27, 2026Insider tradeSEC
8-K · Current reportJul 27, 2026Current reportSEC
S-8 · Registration statement for employee plansJul 24, 2026Offer documentSEC
424B4 · ProspectusJul 24, 2026Offer documentSEC
EFFECT · Notice that a registration is effectiveJul 24, 2026Other filingsSEC
3 · Initial statement of ownershipJul 23, 2026Insider tradeSEC
3 · Initial statement of ownershipJul 23, 2026Insider tradeSEC
3 · Initial statement of ownershipJul 23, 2026Insider tradeSEC
3 · Initial statement of ownershipJul 23, 2026Insider tradeSEC
3 · Initial statement of ownershipJul 23, 2026Insider tradeSEC
3 · Initial statement of ownershipJul 23, 2026Insider tradeSEC
3 · Initial statement of ownershipJul 23, 2026Insider tradeSEC
3 · Initial statement of ownershipJul 23, 2026Insider tradeSEC
3 · Initial statement of ownershipJul 23, 2026Insider tradeSEC
3 · Initial statement of ownershipJul 23, 2026Insider tradeSEC
3 · Initial statement of ownershipJul 23, 2026Insider tradeSEC
FWP · Free writing prospectusJul 23, 2026Offer documentSEC
3 · Initial statement of ownershipJul 23, 2026Insider tradeSEC
S-1MEF · Registration of more shares for the same offeringJul 23, 2026Offer documentSEC
CERT · Exchange's certificate of listingJul 22, 2026Other filingsSEC
8-A12B · Registration of shares for listing on an exchangeJul 20, 2026Other filingsSEC
S-1/A · Registration statement, amendedJul 20, 2026Offer documentSEC
S-1/A · Registration statement, amendedJul 10, 2026Offer documentSEC
S-1 · Registration statementJul 2, 2026Offer documentSEC
DRS/A · Draft registration statement, amendedJun 12, 2026Offer documentSEC
DRS/A · Draft registration statement, amendedMar 6, 2026Offer documentSEC
DRS · Draft registration statementJan 9, 2026Offer documentSEC
DApr 1, 2021Other filingsSEC

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Scribe Therapeutics Inc.’s releases · as of Aug 31, 2026

Common shares
18,931,680
Fully diluted
18,931,680

Fully diluted

LineSharesAs of
Common shares18,931,680Aug 31, 2026

Share count over time

CountShares
Aug 31, 202618,931,680

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
a16z Capital Management, L.L.C.3.08M16.3%US$56.7MSep 30, 2026
Avoro Capital Advisors LLC2.6M13.7%US$47.8MSep 30, 2026
Ra Capital Management, L.P.1.8M9.5%US$33.2MSep 30, 2026
Orbimed Advisors LLC1.35M7.1%US$24.8MSep 30, 2026
Perceptive Advisors LLC920K4.9%US$16.9MSep 30, 2026
ARK787K4.2%US$14.5MSep 30, 2026
Baker Bros. Advisors LP689K3.6%US$12.7MSep 30, 2026
T. Rowe Price685K3.6%US$12.6MSep 30, 2026
BlackRock680K3.6%US$12.5MSep 30, 2026
Vanguard543K2.9%US$9.99MSep 30, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
Sanofi500K2.6%US$9.2MSep 30, 2026
Franklin Templeton380K2.0%US$6.38MSep 30, 2026
Adage Capital Partners Gp, L.L.C.380K2.0%US$6.99MSep 30, 2026
Farallon Capital Management, L.L.C.380K2.0%US$6.99MSep 30, 2026
Geode Capital245K1.3%US$4.52MSep 30, 2026
State Street171K0.90%US$3.15MSep 30, 2026
Alyeska Investment Group, L.P.150K0.79%US$2.76MSep 30, 2026
Menlo Ventures Management, L.P.97,6900.52%US$1.8MSep 30, 2026
TD83,3420.44%US$1.92MSep 30, 2026
Sumitomo Mitsui Trust Group, Inc.74,9100.40%US$1.38MSep 30, 2026
Amova Asset Management Americas, Inc.74,9100.40%US$1.38MSep 30, 2026
Northern Trust74,7210.39%US$1.38MSep 30, 2026
UBS71,0670.38%US$1.31MSep 30, 2026
Nuveen41,4700.22%US$763KSep 30, 2026
IQ EQ FUND MANAGEMENT (IRELAND) Ltd40,8760.22%Sep 30, 2026
Longaeva Partners L.P.34,0340.18%US$626KSep 30, 2026
Schwab31,6440.17%US$582KSep 30, 2026
Bank of America27,5890.15%US$508KSep 30, 2026
Point72 Asset Management, L.P.22,7710.12%US$419KSep 30, 2026
Wells Fargo22,5000.12%US$414KSep 30, 2026
Goldman Sachs21,6350.11%US$398KSep 30, 2026
BNY20,3960.11%US$375KSep 30, 2026
Focus Partners Wealth20,0250.11%US$369KSep 30, 2026
Susquehanna13,6410.07%US$251KSep 30, 2026
Seven Grand Managers, LLC10,0000.05%US$184KSep 30, 2026
Rhumbline Advisers8,8970.05%US$164KSep 30, 2026
Morgan Stanley8,5360.05%US$157KSep 30, 2026
DWS8,2690.04%US$152KSep 30, 2026
JPMorgan6,0280.03%US$139KSep 30, 2026
MetLife Investment Management, LLC5,8140.03%US$107KSep 30, 2026
Citigroup Inc4,7420.03%US$87,277Sep 30, 2026
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.4,6360.02%US$85,326Sep 30, 2026
Kayne Anderson Rudnick Investment Management LLC4,1950.02%US$77,209Sep 30, 2026
Tema ETFS LLC3,0460.02%US$56,062Sep 30, 2026
Strs Ohio2,6000.01%US$47,853Sep 30, 2026
BNP Paribas2,4000.01%US$44,172Sep 30, 2026
Police & Firemen's Retirement System of New Jersey2,2890.01%US$42,129Sep 30, 2026
RBC1,292<0.01%US$24,000Sep 30, 2026
Tower Research Capital LLC (TRC)1,024<0.01%US$18,847Sep 30, 2026
Steward Partners Investment Advisory, LLC1,000<0.01%US$18,405Sep 30, 2026

This page holds 50 of 60 holders. Open Shareholders

Big stakes

StakeStakeSharesDateFiling
Marc L. Andreessen16.30%3.08MSep 30, 2026Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Behzad Aghazadeh
Other companies: Whitehawk Therapeutics, Inc. (Director · Since at least Aug 26, 2021); Immunomedics Inc (Director · Oct 23, 2020 – Oct 23, 2020 · Past)
Director · Since at least Jul 23, 2026
Svetlana Lucas
Other companies: Jasper Therapeutics, Inc. (Board Member · Since at least Jun 18, 2024); aTyr Pharma, Inc. (Director · Since at least Jun 28, 2019)
Chief Business Officer · Since at least Mar 13, 2026
Benjamin L. OakesCo-founder, President and CEO · Since at least Nov 4, 2026
Brett StaahlCo-founder, VP of External Innovation · Since at least Nov 5, 2026
Chitra SharmaSVP of Development · Since at least Nov 5, 2026
David F. SavageCo-Founder, Scientific Advisor · Since at least Nov 5, 2026
David ParrotChief Financial Officer · Since at least Nov 5, 2026
George ManningVP, Controller · Since at least Nov 5, 2026
James WatsonHead of Business and Corporate Development, Life Sciences Portfolio, Andreessen Horowitz · Since at least Jul 23, 2026
Jennifer A. DoudnaCo-founder, Scientific Advisor · Since at least Nov 5, 2026
All 12 people
PersonSeat
Richard HectorHead of IP · Since at least Nov 5, 2026
Sunny MokSVP of Operations · Since at least Nov 5, 2026

Open People

Log in to ask 6ix AI your own questions about Scribe Therapeutics Inc.